Author/Authors :
Namayandeh Seyedeh Mahdieh نويسنده , Alipour Mohammad Reza نويسنده Tuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran , Sarebanhassanabadi Mohammadtaghi نويسنده Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , Lookzadeh Mohammad Hossein نويسنده Department of Pediatrics, Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Pezeshkpour Zohreh نويسنده Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran
Abstract :
Background Persistent pulmonary hypertension of the newborn (PPHN)
occurs in post-term neonates with an incidence of 1 in 500 - 1,500 live
births. The survival rate is approximately 69% after conventional
management of infants suffering from PPHN. Extracorporeal membrane
oxygenation (ECMO) therapy improves survival up to 86%. Methods A total
of 32 neonates with PPHN participated in this study. These neonates were
randomly assigned into two 16-case groups: group A received tadalafil
while group B received sildenafil. A random simple sampling method was
used for the selection of subjects. The severity of tricuspid
regurgitation (TR), main pulmonary artery (MPA) diameter, mean pulmonary
artery pressure (MPAP), and right ventricular end-diastolic diameter
(RVEDD) were assessed by echocardiography before and 6 months after
treatment. Results MPAP decreased after treatment in both groups, but
the mean of changes in PAP in the two groups was not significantly
different (P = 0.48). Both tadalafil and sildenafil significantly
reduced the TR severity, RVEDD, and MPA diameter (P < 0.05), but
the mean of the changes in TR, RVEDD, and MPA in both groups was similar
(P = 0.05). Conclusions Tadalafil and sildenafil can similarly reduce
MPAP, TR severity, RVEDD, and MPA diameter.
